Brochure: CRDMO platform for Oligonucleotide, Peptide and Complex Conjugate
WuXi STA New Modality CRDMO Business Introduction
White paper: Picking the right cdmo partner for integrated and accelerated peptide therapeutic development
Protein therapeutics have played an important role in medicine since the advent of insulin therapy to treat diabetes in the 1920s. More recently, peptides have emerged as valuable therapeutics with attractive drug properties.
A case study: An integrated peptide development enables IND submission in 10 months
A 12-minute webinar presented by Pete Nguyen, Ph.D., Director Business Development Oligo/Peptide, WuXi STA
Presentation: WuXi STA peptide expansion plan announced during DCAT week
Watch this video presented by Jinling Chen, Ph.D., Senior Vice President DP Business and Yu Lu, Senior Vice President Business Operations
Webinar: Novel peptide hit identifcation and lead generating strategies for drug discovery
Watch this webinar presented by Graham Ogg, Professor, MRC Weatherall Institute of Molecular Medicine, University of Oxford and Hui Liao Associate Director, Chemistry Service Unit (CSU), WuXi AppTec
Webinar: Accelerating novel peptides into clinical trials with integrated partnership
Attend our webinar co-presented by Yen-Huei Lin, Ph.D. Exec. Director, Biopharmaceutical Development and Manufacturing at Neuraly and William Fang, Head of Oligo/Peptide Business at WuXi STA about how an integrated CMC partnership was critical in accelerating a novel peptide to phase 1 clinical trial.